News >

EU Panel Grants Positive Opinion to Brigatinib for ALK+ NSCLC

Gina Columbus @ginacolumbusonc
Published: Friday, Sep 21, 2018

Enriqueta Felip, MD, PhDD

Enriqueta Felip, MD, PhD
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended full approval of brigatinib (Alunbrig) as a treatment for patients with advanced ALK-positive non–small cell lung cancer (NSCLC) who are previously treated with crizotinib (Xalkori).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x